| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Florian Schlagenhauf, Martin Dinges, Anne Beck, Torsten Wüstenberg, Eva Friedel, Theresa Dembler, Rahul Sarkar, Jana Wrase, Jürgen Gallinat, Georg Juckel, Andreas Hein. Switching schizophrenia patients from typical neuroleptics to aripiprazole: effects on working memory dependent functional activation. Schizophrenia research. vol 118. issue 1-3. 2010-07-13. PMID:20189356. |
aripiprazole--a partial dopamine antagonist--is a novel antipsychotic, which increases frontal dopamine concentrations in preclinical studies. |
2010-07-13 |
2023-08-12 |
Not clear |
| Derick E Vergne, Raymond F Anto. Aripiprazole: a drug with a novel mechanism of action and possible efficacy for alcohol dependence. CNS & neurological disorders drug targets. vol 9. issue 1. 2010-06-14. PMID:20201815. |
nevertheless, relatively recent pre-clinical data shows that aripiprazole might exert its action by way of agonism, partial agonism, and antagonism at both dopamine and serotonin receptors. |
2010-06-14 |
2023-08-12 |
Not clear |
| Myung-Ji Lee, Chul-Eung Ki. Use of aripiprazole in clozapine induced enuresis: report of two cases. Journal of Korean medical science. vol 25. issue 2. 2010-04-28. PMID:20119596. |
aripiprazole acts as a potential dopamine partial agonist and the dopamine blockade in the basal ganglia might be one of the causes of urinary incontinence and enuresis. |
2010-04-28 |
2023-08-12 |
Not clear |
| Myung-Ji Lee, Chul-Eung Ki. Use of aripiprazole in clozapine induced enuresis: report of two cases. Journal of Korean medical science. vol 25. issue 2. 2010-04-28. PMID:20119596. |
we speculate that aripiprazole functioned as a d2 agonist in hypodopaminergic state of basal ganglia caused by clozapine and maintained dopamine level that would improve enuresis ultimately. |
2010-04-28 |
2023-08-12 |
Not clear |
| Irene Neuner, Andrea Ludolp. [Tics and Tourette's syndrome throughout the life span]. Der Nervenarzt. vol 80. issue 11. 2010-04-27. PMID:19855949. |
first results of some case series with the partial dopamine agonist aripiprazole are encouraging. |
2010-04-27 |
2023-08-12 |
Not clear |
| Matthew W Feltenstein, Phong H Do, Ronald E Se. Repeated aripiprazole administration attenuates cocaine seeking in a rat model of relapse. Psychopharmacology. vol 207. issue 3. 2010-03-23. PMID:19779699. |
aripiprazole (abilify) is an atypical antipsychotic drug characterized by partial agonist activity at dopamine (da) d(2)/d(3) receptors and a low side-effect profile. |
2010-03-23 |
2023-08-12 |
rat |
| Pilar Lopez-Garcia, Carlos Chiclana, Rafael Gonzale. Combined use of ECT with aripiprazole. The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry. vol 10. issue 4 Pt 3. 2010-03-19. PMID:17853257. |
this case report is on the combined use of electroconvulsive treatment (ect) with a partial dopamine agonist, aripiprazole, in the treatment of a 30-year-old man with chronic and refractory paranoid schizophrenia. |
2010-03-19 |
2023-08-12 |
Not clear |
| Chi-Un Pa. A review of the safety and tolerability of aripiprazole. Expert opinion on drug safety. vol 8. issue 3. 2010-03-02. PMID:19505266. |
it seems that the efficacy of aripiprazole for treating schizophrenia is mediated through a combination of partial agonism at dopamine d2 and serotonin 5-ht1a receptors and antagonism at serotonin 5-ht2a receptors. |
2010-03-02 |
2023-08-12 |
Not clear |
| Rajaprabhakaran Rajarethinam, John Dziuba, Suzanne Manji, Albert Pizzuti, Leonard Lachover, Matcheri Keshava. Use of aripiprazole in tardive dyskinesia: an open label study of six cases. The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry. vol 10. issue 4 Pt 2. 2010-03-01. PMID:19492247. |
aripiprazole, a partial dopamine agonist has been reported to help reduce symptoms of tardive dyskinesia (td). |
2010-03-01 |
2023-08-12 |
Not clear |
| Hidehiro Oshibuchi, Ken Inada, Hiroko Sugawara, Jun Ishigook. Aripiprazole and haloperidol suppress excessive dopamine release in the amygdala in response to conditioned fear stress, but show contrasting effects on basal dopamine release in methamphetamine-sensitized rats. European journal of pharmacology. vol 615. issue 1-3. 2009-11-10. PMID:19477171. |
aripiprazole and haloperidol suppress excessive dopamine release in the amygdala in response to conditioned fear stress, but show contrasting effects on basal dopamine release in methamphetamine-sensitized rats. |
2009-11-10 |
2023-08-12 |
rat |
| Hidehiro Oshibuchi, Ken Inada, Hiroko Sugawara, Jun Ishigook. Aripiprazole and haloperidol suppress excessive dopamine release in the amygdala in response to conditioned fear stress, but show contrasting effects on basal dopamine release in methamphetamine-sensitized rats. European journal of pharmacology. vol 615. issue 1-3. 2009-11-10. PMID:19477171. |
aripiprazole is the first antipsychotic drug with an action involving partial dopamine d(2) receptor agonism, thus differing from haloperidol, a typical antipsychotic that shows selective dopamine d(2) receptor full antagonism. |
2009-11-10 |
2023-08-12 |
rat |
| Hidehiro Oshibuchi, Ken Inada, Hiroko Sugawara, Jun Ishigook. Aripiprazole and haloperidol suppress excessive dopamine release in the amygdala in response to conditioned fear stress, but show contrasting effects on basal dopamine release in methamphetamine-sensitized rats. European journal of pharmacology. vol 615. issue 1-3. 2009-11-10. PMID:19477171. |
in the present study, we found that aripiprazole and haloperidol equally suppressed the marked increase in extracellular dopamine levels in fear-conditioned rats, whereas haloperidol increased and aripiprazole decreased tonic dopamine levels. |
2009-11-10 |
2023-08-12 |
rat |
| Hidehiro Oshibuchi, Ken Inada, Hiroko Sugawara, Jun Ishigook. Aripiprazole and haloperidol suppress excessive dopamine release in the amygdala in response to conditioned fear stress, but show contrasting effects on basal dopamine release in methamphetamine-sensitized rats. European journal of pharmacology. vol 615. issue 1-3. 2009-11-10. PMID:19477171. |
in addition, the contrasting effects of haloperidol and aripiprazole on tonic dopamine levels in the amygdala are likely due to the difference in their actions (selective dopamine d(2) receptor full antagonist vs. partial agonist, respectively). |
2009-11-10 |
2023-08-12 |
rat |
| Shubhra Mace, David Taylo. Aripiprazole: dose-response relationship in schizophrenia and schizoaffective disorder. CNS drugs. vol 23. issue 9. 2009-11-09. PMID:19689167. |
aripiprazole exhibits high affinity for dopamine d(2) receptors, with near maximal receptor occupancy at a dose of 30 mg. |
2009-11-09 |
2023-08-12 |
Not clear |
| Susanne Englisch, Christine Esslinger, Dragos Inta, Andrea Weinbrenner, Verena Peus, Alexander Gutschalk, Frederike Schirmbeck, Mathias Zin. Clozapine-induced obsessive-compulsive syndromes improve in combination with aripiprazole. Clinical neuropharmacology. vol 32. issue 4. 2009-10-08. PMID:19644230. |
one suggestive agent for antiobsessive add-on treatment is aripiprazole, a partial agonist at dopamine and serotonin receptors.here, we summarize the courses of 7 patients (6 men; mean age, 37 years; mean duration of psychotic illness, 17 years). |
2009-10-08 |
2023-08-12 |
Not clear |
| Shih-Fen Chen, Yu-Chih Shen, Chia-Hsiang Che. HTR2A A-1438G/T102C polymorphisms predict negative symptoms performance upon aripiprazole treatment in schizophrenic patients. Psychopharmacology. vol 205. issue 2. 2009-10-05. PMID:19387614. |
aripiprazole acts as a partial agonist at dopamine d2 and d3 and serotonin 1a receptors and as an antagonist at serotonin 2a receptors (htr2a). |
2009-10-05 |
2023-08-12 |
Not clear |
| Adeline Etievant, Cécile Bétry, Jørn Arnt, Nasser Haddjer. Bifeprunox and aripiprazole suppress in vivo VTA dopaminergic neuronal activity via D2 and not D3 dopamine autoreceptor activation. Neuroscience letters. vol 460. issue 1. 2009-09-01. PMID:19450663. |
bifeprunox and aripiprazole suppress in vivo vta dopaminergic neuronal activity via d2 and not d3 dopamine autoreceptor activation. |
2009-09-01 |
2023-08-12 |
rat |
| Adeline Etievant, Cécile Bétry, Jørn Arnt, Nasser Haddjer. Bifeprunox and aripiprazole suppress in vivo VTA dopaminergic neuronal activity via D2 and not D3 dopamine autoreceptor activation. Neuroscience letters. vol 460. issue 1. 2009-09-01. PMID:19450663. |
bifeprunox and aripiprazole are two novel antipsychotics presenting partial agonistic activity for the d(2) and d(3) dopamine (da) receptors. |
2009-09-01 |
2023-08-12 |
rat |
| Adeline Etievant, Cécile Bétry, Jørn Arnt, Nasser Haddjer. Bifeprunox and aripiprazole suppress in vivo VTA dopaminergic neuronal activity via D2 and not D3 dopamine autoreceptor activation. Neuroscience letters. vol 460. issue 1. 2009-09-01. PMID:19450663. |
moreover, we have also shown that the d(2/3) receptor antagonist haloperidol prevents the inhibitory effects of these antipsychotics, confirming their partial d(2)-like agonistic activities [l. dahan, h. husum, o. mnie-filali, j. arnt, p. hertel, n. haddjeri, effects of bifeprunox and aripiprazole on rat serotonin and dopamine neuronal activity and anxiolytic behaviour, j. psychopharmacol. |
2009-09-01 |
2023-08-12 |
rat |
| Taku Nagai, Rina Murai, Kanae Matsui, Hiroyuki Kamei, Yukihiro Noda, Hiroshi Furukawa, Toshitaka Nabeshim. Aripiprazole ameliorates phencyclidine-induced impairment of recognition memory through dopamine D1 and serotonin 5-HT1A receptors. Psychopharmacology. vol 202. issue 1-3. 2009-08-05. PMID:18679658. |
aripiprazole ameliorates phencyclidine-induced impairment of recognition memory through dopamine d1 and serotonin 5-ht1a receptors. |
2009-08-05 |
2023-08-12 |
Not clear |